Conflict of Interest Disclosures: Dr Harrington reported receiving personal fees from Bristol Myers Squibb, Arch Oncology,
Codiak, Inzen, Merck Serono, MSD, Replimune, AstraZeneca, Boehringer Ingelheim, and
Pfizer; receiving honoraria from Boehringer Ingelheim, Bristol Myers Squibb, Merck
Serono, and MSD; receiving meeting attendance and/or travel support from Merck Serono,
MSD, and Replimune; participating in data safety monitoring board or advisory board
meetings for Arch Oncology, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb,
Codiak, Inzen, Merck Serono, MSD, Pfizer, and Replimune; and receiving grants from
AstraZeneca, MSD, Boehringer Ingelheim, Replimune, and MSD. Dr Ferris reported receiving
personal fees from Achilles Therapeutics, Adagene Inc, Aduro Biotech, Bicara Therapeutics,
Bristol Myers Squibb, Brooklyn ImmunoTherapeutics LLC, Catenion, Coherus BioSciences,
EMD Serono, Everest Clinical Research Corporation, F. Hoffmann-LaRoche, Genocea Biosciences,
Hookipa Biotech, Instil Bio, Kowa Research Institute, Lifescience Dynamics Limited,
MacroGenics, MeiraGTx LLC, Merck, Mirati Therapeutics, Nanobiotix, Novartis Pharmaceutical
Corporation, Novasenta, Numab Therapeutics, Oncocyte Corporation, Pfizer, PPD Development,
Rakuten Medical, Sanofi, Seagen, SIRPant Immunotherapeutics, Vir Biotechnology, and
Zymeworks; receiving grants from AstraZeneca/MedImmune, Bristol Myers Squibb, Merck,
Novasenta, and Tesaro; serving on the advisory board of Coherus BioSciences, Hookipa,
Instil Bio, Lifescience Dynamics, MacroGenics, MeiraGTx LLC, Oncocyte Corporation,
Pfizer, Rakuten Medical, Seagen, SIRPant Immunotherapeutics, and Vir Biotechnology;
serving on the data safety monitoring board for and having stock in Mirror Biologics;
having stock in or receiving stock options from Novasenta; serving on the advisory
board for and receiving research funding from Numab Therapeutics; and serving as president-elect
of the American Head and Neck Society. Prof Gillison reported receiving clinical trial
support to the institution from Bristol Myers Squibb during the conduct of the study
and from Gilead Sciences, Seagen, Bristol Myers Squibb, Genentech, Kura Oncology,
and Agenus outside the submitted work; receiving personal fees from EMD Serono, Shattuck
Labs, BioNTech, Kura Oncology, LLX Solutions, Eisai Medical Research, Ipsen Biopharmaceuticals,
Nektar Therapeutics, Debiopharm, Coherus BioSciences, Mirati Therapeutics, Sensei
Biotherapeutics, Seagen, Istari Oncology, iTeos Therapeutics, Caladrius Biosciences,
Exelixis, Amgen, Aspyrian Therapeutics, AstraZeneca, Bayer, Bicara Therapeutics, Celgene,
Genocea Biosciences, Gilead Sciences, Healthcare Pharmaceuticals, Merck, NewLink Genetics,
OncLive Intellisphere, Roche, and TRM Oncology; receiving honoraria from OncLive and
Roche; having patents issued for plasmid DNA and patents pending for oral human papillomavirus
infection detection and screening; participating on data safety monitoring boards
or advisory boards for BioMimetix, Kura Oncology, NRG, Seagen, Sensei Biotherapeutics,
and SQZ Biotech; receiving options from Sensei Biotherapeutics; and receiving research
funding to the institution from Agenus, Bristol Myers Squibb, Cullinan Labs, Genentech,
Genocea Biosciences, Kura Oncology, LaRoche, NRG, and the University of Cincinnati.
Dr Tahara reported receiving personal fees from Bristol Myers Squibb and grants from
Ono Pharmaceutical during the conduct of the study; receiving personal fees from Bayer,
Lilly, Merck, Pfizer, Rakuten Medical, Genmab, Nektar, Janssen, Astellas, Eisai, and
MSD outside the submitted work; receiving honoraria from AstraZeneca, Bayer, Boehringer
Ingelheim, Bristol Myers Squibb, Eli Lilly, Genmab, GlaxoSmithKline (GSK), Merck,
MSD, Ono Pharmaceutical, Pfizer, and Rakuten Medical; and receiving grants or contracts
to the institution from AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, GSK,
Merck, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Rakuten Medical. Dr Argiris
reported receiving research support from Bristol Myers Squibb and speaker fees from
Merck. Dr Fayette reported receiving personal fees and nonfinancial support from MSD
and AstraZeneca; grants, personal fees, and nonfinancial support from Bristol Myers
Squibb; and personal fees from Innate Pharma, Roche, Hookipa, Merck, F-star, and Sanofi.
Dr Schenker reported receiving grants from Bristol Myers Squibb during the conduct
of the study and grants or fees from Eli Lilly, MSD, Roche, Novartis, Regeneron, Sanofi,
Merck Serono, AstraZeneca, GSK, Amgen, Astellas, AbbVie, Bioven, BeiGene, Bayer, Clovis,
Gilead, Mylan, Pfizer, PharmaMar, Samsung Pharmaceuticals, and Tesaro outside the
submitted work. Dr Bratland reported receiving grants from Bristol Myers Squibb during
the conduct of the study and from Merck Sharp & Dohme and GSK outside the submitted
work; receiving personal fees from Sanofi for serving on the advisory board; and serving
as president of the Scandinavian Society for Head and Neck Oncology. Dr Grell reported
receiving funding from Bristol Myers Squibb during the conduct of the study and personal
fees from Roche and Servier outside the submitted work. Dr Even reported receiving
personal fees from Bristol Myers Squibb, MSD, and Merck Serono; travel fees from Bristol
Myers Squibb and MSD; nonfinancial support from MSD and Merck Serono; and participating
in data safety monitoring board or advisory board meetings for Bristol Myers Squibb,
Merck Serono, Novartis, F-Star Therapeutics, and MSD. Dr Chung reported receiving
a clinical trial contract from Bristol Myers Squibb to the Moffitt Cancer Center during
the conduct of the study and personal fees for participating on ad hoc scientific
advisory boards from Merck, Sanofi, Exelixis, Brooklyn ImmunoTherapeutics, Fulgent,
GenMap, and Aveo outside the submitted work. Dr Redman reported receiving institutional
funding from Bristol Myers Squibb during the conduct of the study and from Merck,
Pfizer, Daiichi Sankyo, Iovance, Molecular Templates, RAPT Therapeutics, Inspirna,
and ALX Oncology outside the submitted work. Dr Grant reported receiving honoraria
from Bristol Myers Squibb. Dr de Azevedo reported participating in data safety monitoring
board or advisory board meetings for Gilead Brazil. Dr Soulières reported receiving
grants to the institution and personal fees for advisory board or clinical study board
participation from Bristol Myers Squibb during the conduct of the study and from Merck
and Adlai-Nortye outside the submitted work. Dr Hansen reported receiving research
support to the institution from Bristol Myers Squibb, Merck, AstraZeneca, Pfizer,
Roche, Boehringer Ingelheim, Janssen, Eisai, Novartis, POINT Biopharma, GSK, and MedImmune
outside the submitted work and receiving consulting fees from Eisai, GSK, and Merck.
Dr Wei reported receiving stocks from Bristol Myers Squibb. Dr Khan reported having
stock in Bristol Myers Squibb. Dr Miller-Moslin reported having stock in Bristol Myers
Squibb. Dr Roberts reported being employed by Takeda outside the submitted work. Dr
Haddad reported receiving grants from Bristol Myers Squibb during the conduct of the
study; receiving personal fees for consulting or advisory board participation from
Bristol Myers Squibb, Merck, EMD, Eisai, Celgene, Kura, AstraZeneca, Genentech, Boehringer
Ingelheim, Exelixis, Blue DOT, and Nanobiotix outside the submitted work; having a
leadership role in the National Comprehensive Cancer Network; receiving consulting
fees from Achilles Therapeutics, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim,
Bristol Myers Squibb, Celgene, Coherus BioSciences, Eisai, EMD Serono, Genentech,
Gilead Sciences, GSK, Immunomic Therapeutics, Loxo, Merck, Mirati, Pfizer, and Vaccinex;
receiving royalties or having patents or other intellectual property from UpToDate;
receiving research funding to the institution from AstraZeneca, Boehringer Ingelheim,
Bristol Myers Squibb, Celgene, Genentech, Kura Oncology, Merck, and Pfizer; and receiving
fees for serving as chair of the data safety monitoring board for 2 trials run by
Nanobiotix and ISA Pharmaceuticals. No other disclosures were reported.